Vaxcyte, Inc. — FY2021 Form 10-K
Reporting period: Year ended December 31, 2021; filed February 28, 2022. The filing is an annual report, not a standalone fourth-quarter report, and does not provide a clear quarterly financial breakdown. Vaxcyte is a clinical-stage vaccine company with no approved products or product revenue.
Business context and pipeline
The company is developing bacterial vaccines using its cell-free protein synthesis platform. Its lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine; other programs include VAX-XP (designed for more than 30 strains), VAX-A1 for Group A Strep, and VAX-PG for periodontitis. VAX-24 remained preclinical at year-end; its FDA IND clearance and adult Phase 1/2 trial initiation occurred after year-end, in January and February 2022, respectively.
Financial performance and liquidity
Amounts below are in U.S. dollars; financial statement amounts were reported in thousands.
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Product revenue | None | None | No product revenue |
| Research and development expense | $78.4 million | $73.6 million | +6.6% |
| General and administrative expense | $25.3 million | $16.0 million | +57.7% |
| Total operating expenses | $103.7 million | $89.6 million | +15.7% |
| Net loss | $100.1 million | $89.2 million | Loss increased 12.2% |
| Net loss per share, basic and diluted | $1.93 | $3.02 | Per-share loss decreased as weighted-average shares rose |
| Net cash used in operating activities | $121.4 million | $46.6 million | Cash use increased |
R&D expense rose despite lower product and clinical development costs, primarily reflecting higher personnel, facility, consumables, and laboratory costs. G&A growth included personnel and stock-based compensation, public-company compliance, technology infrastructure, and directors’ and officers’ insurance. There are no meaningful operating margins to assess given the absence of revenue.
At December 31, 2021, cash and cash equivalents were $69.0 million and investments were $204.1 million, totaling $273.1 million. Current assets were $256.3 million versus current liabilities of $28.7 million. Stockholders’ equity was $284.0 million; accumulated deficit was $298.6 million. The company reported no conventional debt; operating lease liabilities were $16.8 million, with $20.3 million of undiscounted lease payments. Management said existing cash, cash equivalents, and investments should fund current plans for at least 12 months from the filing date, but additional capital will be needed before pivotal trials.
FY2021 cash flows included $212.3 million used in investing, principally net purchases of investments, and $17.8 million provided by financing, primarily ATM proceeds. The $316.3 million decline in cash and restricted cash largely reflects movement of funds into investments, rather than a comparable reduction in cash plus investments. The company raised $13.9 million net through its ATM program during 2021. After year-end, it raised approximately $107.6 million net through a public offering and underwriters’ option exercise.
Material changes, outlook, and risks
- Net loss widened from $89.2 million to $100.1 million, while operating expenses increased 15.7%. The foreign-currency result improved by $4.0 million year over year, from a $2.4 million loss to a $1.7 million gain, partly cushioning operating losses. Grant income declined from $2.5 million to $1.6 million.
- VAX-24 manufacturing and release of clinical drug product were completed in Q4 2021. The company reported earlier process adjustments and manufacturing delays associated with Lonza scheduling and capacity constraints; it relies heavily on third parties for manufacturing and supply.
- Management expected VAX-24 adult Phase 1/2 topline safety, tolerability, and immunogenicity results by year-end 2022. A separate study in adults 65 and older was expected to produce topline results in the first half of 2023, conditional on Phase 1 progress. A pediatric IND was anticipated in the first half of 2023, subject to FDA interaction and adult results.
- VAX-A1 entered IND-enabling work in the second half of 2021. CARB-X revised potential total funding through Phase 1 from $29.7 million to $13.9 million in January 2022. VAX-PG final candidate nomination was expected by year-end 2022.
- Key uncertainties include clinical safety and efficacy, FDA acceptance of surrogate immune endpoints instead of field efficacy trials, manufacturing scale-up and third-party availability, additional financing, competition from larger vaccine makers, intellectual-property protection, reimbursement, and COVID-19-related disruption. VAX-24 is central to the company’s prospects, but had not yet been tested in humans at year-end.
- The company reported audited financial statements with an unqualified audit opinion and effective internal control over financial reporting. The auditor identified accrued manufacturing expenses as a critical audit matter; the year-end accrual was $4.4 million. No material litigation was reported.
Important facts for investors to verify
- Whether VAX-24 clinical results meet prespecified safety and immunogenicity objectives, and how results compare with Prevnar 20.
- Whether the FDA accepts the proposed development and regulatory path, including use of surrogate immune endpoints and any pediatric plans.
- Updated cash, investment balances, operating cash burn, and financing runway after the 2022 offering; assess potential dilution from equity financing.
- Progress on manufacturing scale-up, Lonza capacity and costs, and the availability of alternative suppliers for critical materials.
- CARB-X funding available after its revised limits, and the timing and spending requirements for VAX-A1 and other pipeline programs.
- Future disclosures on lease commitments, clinical/manufacturing accruals, and any material changes in risks or guidance.